FDA Approves Gilead's Bixlenvo HIV Pill
Analysis based on 6 articles · First reported Aug 27, 2026 · Last updated Aug 29, 2026
The approval strengthens Gilead's HIV franchise, potentially boosting revenue and market share in the HIV treatment market. It may pressure competitors like Merck, which offers a similar once-daily pill, by providing a new option for patients with complex regimens.
The U.S. United States — Food and Drug Administration approved Gilead Sciences' once-daily oral combination pill Bixlenvo for the treatment of adults with suppressed HIV. Bixlenvo combines bictegravir and lenacapavir, offering a simpler once-daily regimen for patients who may be on complex multi-pill therapies due to drug resistance. The approval was based on two late-stage studies showing Bixlenvo was as effective as complex regimens or Biktarvy in maintaining viral suppression after 48 weeks. Gilead expects Bixlenvo to be available within days, with a wholesale acquisition cost of $4,595 for a 30-day supply. The drug enters a competitive HIV market that includes Merck's Idvynso, a once-daily two-drug pill approved in April. Gilead's strategy aims to expand its HIV portfolio, leveraging lenacapavir as a foundation.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard